Tumor Lysis Syndrome after Hepatic Artery Embolization in a Patient with Neuroendocrine Tumor of Unknown Primary

Odeth Barrett-Campbell¹, Joselle Cook¹, Jordonna Brown¹, Evelyn Taiwo² and Samy I. McFarlane^1,

¹Department of Medicine, SUNY Downstate Medical Center, Brooklyn, NY 11203, USA

²Division of Hematology and Oncology, SUNY Downstate Medical Center, Brooklyn, NY 11203, USA

Cite this paper

Odeth Barrett-Campbell, Joselle Cook, Jordonna Brown, Evelyn Taiwo and Samy I. McFarlane. Tumor Lysis Syndrome after Hepatic Artery Embolization in a Patient with Neuroendocrine Tumor of Unknown Primary. American Journal of Medical Case Reports. 2019; 7(7):135-137. doi: 10.12691/AJMCR-7-7-4

Abstract

While tumor lysis syndrome is a relatively common oncologic emergency that may occur spontaneously or resulting from cancer directed therapy, it is relatively unusual occurrence in solid tumors, especially neuroendocrine tumors. It is also particularly rare after hepatic trans-arterial embolization. We report a case of a 60-year-old man who had hepatic trans-arterial embolization for metastatic neuroendocrine tumor of the liver of unknown primary, who developed tumor lysis along with post-embolization syndrome. He received aggressive intravenous fluid resuscitation, allopurinol and rasburicase for his tumor lysis syndrome but subsequently had acute renal failure for which he underwent renal replacement therapy. The patient responded well to treatment with complete resolution of his post-embolization syndrome, tumor lysis syndrome and acute renal failure. Our case report highlights the need to consider tumor lysis syndrome in solid tumors. It should be readily recognized and treated given the associated high risk of morbidity and mortality.

Keywords

tumor lysis syndrome, hepatic artery embolization, neuroendocrine tumor

Copyright

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References

[1]	Tiu R.V., Mountantonakis S.E., Dunbar A. J., Schreiber M. J. (2007). Tumor lysis syndrome. Seminars in Thrombosis and hemostasis. 33 (4): 397-407.
[2]	Mirrakhimov, A.E., Ali, A. M., Khan, M., Barbaryan, A. (2014). Tumor lysis syndrome in solid tumors: An up to date review of the literature. Rare Tumors, 6(2), 5389.
[3]	Spigel, D., Hainsworth J. & Greco A. (2009). Neuroendocrine carcinoma of unknown primary site. Seminars in Oncology, 36(1), 52-59.
[4]	Kim J.Y. & Hong S. (2015) Recent Updates on Neuroendocrine Tumors from the Gastrointestinal and Pancreatobiliary Tracts. Archives of Pathology and Laboratory Medicine. Volume 140.
[5]	Strosberg J., Nasir A., Hodul P. & Kvols L. (2008). Biology and Treatment of Metastatic Gastrointestinal Neuroendocrine Tumors. Gastrointestinal Cancer Research, 2 (3).
[6]	Nazario J., Gupta S. (2010). Transarterial liver-directed therapies of neuroendocrine hepatic metastases. Seminars in Oncology. 37 (2): 118-126.
[7]	Lewis, M. A., & Hobday, T.J. (2012). Treatment of neuroendocrine tumor liver metastases. International Journal of Hepatology, 1-12.
[8]	Veenendaal, L., Borel Rinkes I., Lips C., & van Hillegersberg R. (2006). Liver metastases of neuroendocrine tumors; early reduction of tumor load to improve life expectancy. World Journal of Surgical Oncology, 4, 35.
[9]	Lewis, M. A., Jaramillo, S., Roberts, L., Fleming, C.J., Rubin, J., Grothey, A. (2012). Hepatic artery embolization for neuroendocrine tumors: Postprocedural management and complications. The Oncologist, 17(5), 725-731.
[10]	Frilling A., Clift A. (2015). Therapeutic strategies for hepatic neuroendocrine liver metastases. American Cancer Society. 121: 1172-86.
[11]	Vogl T.J., Naguib NN., Zangos S., Eichler K., Hedayati A. & Nour-Eldin NE. (2008). Liver metastases of neuroendocrine carcinomas: Interventional treatment via transarterial embolization, chemoembolization and thermal ablation. European Journal of Radiology. 72 (517-528).
[12]	Del Prete M., Fiore F., Modica R., Marotta V., Marciello F., Ramundo V…….Fagiano A. (2014). Hepatic arterial embolization in patients with neuroendocrine tumors. J Exp Clin Cancer Res. 19; 33:43.
[13]	Fiore F., Del Prete M., Franco R., Marotta V., Marciello F., Di Sarno A……Faggiano A. (2014). Transarterial embolization (TAE) is equally effective and slightly safer than transarterial chemoembolization (TACE) to manage liver metastases in neuroendocrine tumors. Endocrine. 47(1): 177-82.
[14]	Shiba H., Isheba Y., Wakiyama S., Sakamoto T., Misawa T., Yanaga K. (2008). Acute tumor lysis syndrome after transarterial chemoembolization for hepatocellular carcinoma. The official Journal of the Japanese Cancer association.
[15]	Hseih P., Hung K., Chen Y. Tumor lysis syndrome after transarterial chemoembolization of hepatocellular carcinoma: case reports and literature review. (2009). World J Gastroenterol. 15(37): 4726-4728.